---
document_datetime: 2025-12-02 05:14:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/galliapharm.html
document_name: galliapharm.html
version: success
processing_time: 0.1019705
conversion_datetime: 2025-12-27 21:19:03.360107
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# GalliaPharm

[RSS](/en/individual-human-medicine.xml/243390)

##### Authorised

This medicine is authorised for use in the European Union

gallium (68Ga) chloride / germanium (68Ge) chloride Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on GalliaPharm](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

GalliaPharm is a so-called 'radionuclide generator', a medicine used to obtain a solution containing gallium ( 68 Ga) chloride, a radioactive substance. GalliaPharm and the obtained gallium ( 68 Ga) chloride solution are not intended for direct use in patients.

The gallium ( 68 Ga) chloride solution is used for radiolabelling other medicines, which are used during the body scan known as positron-emission tomography (PET). Radiolabelling is a technique that tags molecules with a radioactive substance.

GalliaPharm contains germanium ( 68 Ge) chloride / gallium ( 68 Ga) chloride.

Expand section

Collapse section

## How is GalliaPharm used?

GalliaPharm and the obtained gallium ( 68 Ga) chloride solution should only be handled by specialists with appropriate training and expertise and can only be used in a designated authorised facility. Detailed instructions for use are included in the Summary of Product Characteristics (information for healthcare professionals).

## How does GalliaPharm work?

GalliaPharm provides a gallium ( 68 Ga) chloride solution, which is used for radiolabelling other medicines. These radiolabelled medicines can recognise and attach to certain cells in the body. The low amount of radioactivity present in the 68 Ga-labelled medicine can be detected during PET body scans, helping doctors with the diagnosis and monitoring of various diseases, including cancer.

## What benefits of GalliaPharm have been shown in studies?

Since 68 Ga-containing solutions obtained from 68 Ge / 68 Ga-generators have been used for radiolabelling for several years, the company that markets GalliaPharm provided data from the medical literature showing its utility in clinical practice. The company also provided data on the quality of the medicine, and data from an animal model (rats) showing that, due to the extremely low amount of 68 Ga, no effects are expected even after accidental injection of the radioactive solution obtained from GalliaPharm.

## What are the risks associated with GalliaPharm?

Exposure to radiation may contribute to a risk of cancer or hereditary defects.

Side effects following the use of a medicine radiolabelled using the gallium ( 68 Ga) chloride solution obtained from GalliaPharm will depend on the specific medicine being used. For more information about possible side effects, read the package leaflet of the respective radiolabelled medicine.

## Why is GalliaPharm authorised in the EU?

68 Ga has a short half-life, meaning that it quickly loses the radioactivity necessary for radiolabelling. The use of a 68 Ge/ 68 Ga generator such as GalliaPharm is a suitable way to make gallium ( 68 Ga) chloride solution readily available for radiolabelling. GalliaPharm is expected to facilitate the process of radiolabelling in authorised facilities and to improve access to cancer diagnostics, which is considered a clinically relevant benefit. Potential risks to patients are considered low, as these can be minimised through quality control procedures and adequate instructions and training of the medical personnel handling GalliaPharm.

The European Medicines Agency therefore decided that GalliaPharm's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of GalliaPharm?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of GalliaPharm have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of GalliaPharm are continuously monitored and any necessary action will be taken to protect patients.

## Other information about GalliaPharm

GalliaPharm received a marketing authorisation valid throughout the EU on 01 August 2024.

GalliaPharm : EPAR - Medicine overview

Reference Number: EMA/267745/2024

English (EN) (120.4 KB - PDF)

**First published:** 22/08/2024

[View](/en/documents/overview/galliapharm-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-63)

български (BG) (149.46 KB - PDF)

**First published:**

22/08/2024

[View](/bg/documents/overview/galliapharm-epar-medicine-overview_bg.pdf)

español (ES) (120 KB - PDF)

**First published:**

22/08/2024

[View](/es/documents/overview/galliapharm-epar-medicine-overview_es.pdf)

čeština (CS) (148.76 KB - PDF)

**First published:**

22/08/2024

[View](/cs/documents/overview/galliapharm-epar-medicine-overview_cs.pdf)

dansk (DA) (120.41 KB - PDF)

**First published:**

22/08/2024

[View](/da/documents/overview/galliapharm-epar-medicine-overview_da.pdf)

Deutsch (DE) (122.62 KB - PDF)

**First published:**

22/08/2024

[View](/de/documents/overview/galliapharm-epar-medicine-overview_de.pdf)

eesti keel (ET) (117.77 KB - PDF)

**First published:**

22/08/2024

[View](/et/documents/overview/galliapharm-epar-medicine-overview_et.pdf)

ελληνικά (EL) (150.17 KB - PDF)

**First published:**

22/08/2024

[View](/el/documents/overview/galliapharm-epar-medicine-overview_el.pdf)

français (FR) (120.69 KB - PDF)

**First published:**

22/08/2024

[View](/fr/documents/overview/galliapharm-epar-medicine-overview_fr.pdf)

hrvatski (HR) (139.65 KB - PDF)

**First published:**

22/08/2024

[View](/hr/documents/overview/galliapharm-epar-medicine-overview_hr.pdf)

italiano (IT) (118.83 KB - PDF)

**First published:**

22/08/2024

[View](/it/documents/overview/galliapharm-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (153.24 KB - PDF)

**First published:**

22/08/2024

[View](/lv/documents/overview/galliapharm-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (139.01 KB - PDF)

**First published:**

22/08/2024

[View](/lt/documents/overview/galliapharm-epar-medicine-overview_lt.pdf)

magyar (HU) (138.52 KB - PDF)

**First published:**

22/08/2024

[View](/hu/documents/overview/galliapharm-epar-medicine-overview_hu.pdf)

Malti (MT) (140.21 KB - PDF)

**First published:**

22/08/2024

[View](/mt/documents/overview/galliapharm-epar-medicine-overview_mt.pdf)

Nederlands (NL) (120.47 KB - PDF)

**First published:**

22/08/2024

[View](/nl/documents/overview/galliapharm-epar-medicine-overview_nl.pdf)

polski (PL) (130.5 KB - PDF)

**First published:**

22/08/2024

[View](/pl/documents/overview/galliapharm-epar-medicine-overview_pl.pdf)

português (PT) (120.62 KB - PDF)

**First published:**

22/08/2024

[View](/pt/documents/overview/galliapharm-epar-medicine-overview_pt.pdf)

română (RO) (144.07 KB - PDF)

**First published:**

22/08/2024

[View](/ro/documents/overview/galliapharm-epar-medicine-overview_ro.pdf)

slovenčina (SK) (148.86 KB - PDF)

**First published:**

22/08/2024

[View](/sk/documents/overview/galliapharm-epar-medicine-overview_sk.pdf)

slovenščina (SL) (137.49 KB - PDF)

**First published:**

22/08/2024

[View](/sl/documents/overview/galliapharm-epar-medicine-overview_sl.pdf)

Suomi (FI) (117.69 KB - PDF)

**First published:**

22/08/2024

[View](/fi/documents/overview/galliapharm-epar-medicine-overview_fi.pdf)

svenska (SV) (118.56 KB - PDF)

**First published:**

22/08/2024

[View](/sv/documents/overview/galliapharm-epar-medicine-overview_sv.pdf)

GalliaPharm : EPAR - Risk management plan

English (EN) (1.7 MB - PDF)

**First published:** 22/08/2024

[View](/en/documents/rmp/galliapharm-epar-risk-management-plan_en.pdf)

## Product information

GalliaPharm : EPAR - Product Information

English (EN) (1.51 MB - PDF)

**First published:** 22/08/2024

[View](/en/documents/product-information/galliapharm-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-59)

български (BG) (1.56 MB - PDF)

**First published:**

22/08/2024

[View](/bg/documents/product-information/galliapharm-epar-product-information_bg.pdf)

español (ES) (1.31 MB - PDF)

**First published:**

22/08/2024

[View](/es/documents/product-information/galliapharm-epar-product-information_es.pdf)

čeština (CS) (1.46 MB - PDF)

**First published:**

22/08/2024

[View](/cs/documents/product-information/galliapharm-epar-product-information_cs.pdf)

dansk (DA) (1.33 MB - PDF)

**First published:**

22/08/2024

[View](/da/documents/product-information/galliapharm-epar-product-information_da.pdf)

Deutsch (DE) (1.31 MB - PDF)

**First published:**

22/08/2024

[View](/de/documents/product-information/galliapharm-epar-product-information_de.pdf)

eesti keel (ET) (1.34 MB - PDF)

**First published:**

22/08/2024

[View](/et/documents/product-information/galliapharm-epar-product-information_et.pdf)

ελληνικά (EL) (1.53 MB - PDF)

**First published:**

22/08/2024

[View](/el/documents/product-information/galliapharm-epar-product-information_el.pdf)

français (FR) (1.32 MB - PDF)

**First published:**

22/08/2024

[View](/fr/documents/product-information/galliapharm-epar-product-information_fr.pdf)

hrvatski (HR) (1.38 MB - PDF)

**First published:**

22/08/2024

[View](/hr/documents/product-information/galliapharm-epar-product-information_hr.pdf)

íslenska (IS) (1.28 MB - PDF)

**First published:**

22/08/2024

[View](/is/documents/product-information/galliapharm-epar-product-information_is.pdf)

italiano (IT) (1.36 MB - PDF)

**First published:**

22/08/2024

[View](/it/documents/product-information/galliapharm-epar-product-information_it.pdf)

latviešu valoda (LV) (1.42 MB - PDF)

**First published:**

22/08/2024

[View](/lv/documents/product-information/galliapharm-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.4 MB - PDF)

**First published:**

22/08/2024

[View](/lt/documents/product-information/galliapharm-epar-product-information_lt.pdf)

magyar (HU) (1.55 MB - PDF)

**First published:**

22/08/2024

[View](/hu/documents/product-information/galliapharm-epar-product-information_hu.pdf)

Malti (MT) (1.51 MB - PDF)

**First published:**

22/08/2024

[View](/mt/documents/product-information/galliapharm-epar-product-information_mt.pdf)

Nederlands (NL) (1.37 MB - PDF)

**First published:**

22/08/2024

[View](/nl/documents/product-information/galliapharm-epar-product-information_nl.pdf)

norsk (NO) (1.35 MB - PDF)

**First published:**

22/08/2024

[View](/no/documents/product-information/galliapharm-epar-product-information_no.pdf)

polski (PL) (1.52 MB - PDF)

**First published:**

22/08/2024

[View](/pl/documents/product-information/galliapharm-epar-product-information_pl.pdf)

português (PT) (1.36 MB - PDF)

**First published:**

22/08/2024

[View](/pt/documents/product-information/galliapharm-epar-product-information_pt.pdf)

română (RO) (1.51 MB - PDF)

**First published:**

22/08/2024

[View](/ro/documents/product-information/galliapharm-epar-product-information_ro.pdf)

slovenčina (SK) (1.49 MB - PDF)

**First published:**

22/08/2024

[View](/sk/documents/product-information/galliapharm-epar-product-information_sk.pdf)

slovenščina (SL) (1.46 MB - PDF)

**First published:**

22/08/2024

[View](/sl/documents/product-information/galliapharm-epar-product-information_sl.pdf)

Suomi (FI) (1.27 MB - PDF)

**First published:**

22/08/2024

[View](/fi/documents/product-information/galliapharm-epar-product-information_fi.pdf)

svenska (SV) (1.35 MB - PDF)

**First published:**

22/08/2024

[View](/sv/documents/product-information/galliapharm-epar-product-information_sv.pdf)

01/08/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

GalliaPharm : EPAR - All Authorised presentations

English (EN) (68.5 KB - PDF)

**First published:** 22/08/2024

[View](/en/documents/all-authorised-presentations/galliapharm-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-961)

български (BG) (73.29 KB - PDF)

**First published:**

22/08/2024

[View](/bg/documents/all-authorised-presentations/galliapharm-epar-all-authorised-presentations_bg.pdf)

español (ES) (61.57 KB - PDF)

**First published:**

22/08/2024

[View](/es/documents/all-authorised-presentations/galliapharm-epar-all-authorised-presentations_es.pdf)

čeština (CS) (75.7 KB - PDF)

**First published:**

22/08/2024

[View](/cs/documents/all-authorised-presentations/galliapharm-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (60.83 KB - PDF)

**First published:**

22/08/2024

[View](/da/documents/all-authorised-presentations/galliapharm-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (62.87 KB - PDF)

**First published:**

22/08/2024

[View](/de/documents/all-authorised-presentations/galliapharm-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (60.25 KB - PDF)

**First published:**

22/08/2024

[View](/et/documents/all-authorised-presentations/galliapharm-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (83.95 KB - PDF)

**First published:**

22/08/2024

[View](/el/documents/all-authorised-presentations/galliapharm-epar-all-authorised-presentations_el.pdf)

français (FR) (63.29 KB - PDF)

**First published:**

22/08/2024

[View](/fr/documents/all-authorised-presentations/galliapharm-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (80.75 KB - PDF)

**First published:**

22/08/2024

[View](/hr/documents/all-authorised-presentations/galliapharm-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (60.71 KB - PDF)

**First published:**

22/08/2024

[View](/is/documents/all-authorised-presentations/galliapharm-epar-all-authorised-presentations_is.pdf)

italiano (IT) (63.95 KB - PDF)

**First published:**

22/08/2024

[View](/it/documents/all-authorised-presentations/galliapharm-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (82.07 KB - PDF)

**First published:**

22/08/2024

[View](/lv/documents/all-authorised-presentations/galliapharm-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (82.99 KB - PDF)

**First published:**

22/08/2024

[View](/lt/documents/all-authorised-presentations/galliapharm-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (78.88 KB - PDF)

**First published:**

22/08/2024

[View](/hu/documents/all-authorised-presentations/galliapharm-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (86.96 KB - PDF)

**First published:**

22/08/2024

[View](/mt/documents/all-authorised-presentations/galliapharm-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (59.91 KB - PDF)

**First published:**

22/08/2024

[View](/nl/documents/all-authorised-presentations/galliapharm-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (60.95 KB - PDF)

**First published:**

22/08/2024

[View](/no/documents/all-authorised-presentations/galliapharm-epar-all-authorised-presentations_no.pdf)

polski (PL) (87.03 KB - PDF)

**First published:**

22/08/2024

[View](/pl/documents/all-authorised-presentations/galliapharm-epar-all-authorised-presentations_pl.pdf)

português (PT) (62 KB - PDF)

**First published:**

22/08/2024

[View](/pt/documents/all-authorised-presentations/galliapharm-epar-all-authorised-presentations_pt.pdf)

română (RO) (71.72 KB - PDF)

**First published:**

22/08/2024

[View](/ro/documents/all-authorised-presentations/galliapharm-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (78.67 KB - PDF)

**First published:**

22/08/2024

[View](/sk/documents/all-authorised-presentations/galliapharm-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (81.39 KB - PDF)

**First published:**

22/08/2024

[View](/sl/documents/all-authorised-presentations/galliapharm-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (60.71 KB - PDF)

**First published:**

22/08/2024

[View](/fi/documents/all-authorised-presentations/galliapharm-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (60.08 KB - PDF)

**First published:**

22/08/2024

[View](/sv/documents/all-authorised-presentations/galliapharm-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine GalliaPharm Active substance

- gallium (68Ga) chloride
- germanium (68Ge) chloride

International non-proprietary name (INN) or common name

- gallium (68Ga) chloride
- germanium (68Ge) chloride

Therapeutic area (MeSH) Radionuclide Imaging Anatomical therapeutic chemical (ATC) code V09X

### Pharmacotherapeutic group

Other diagnostic radiopharmaceuticals

### Therapeutic indication

This radionuclide generator is not intended for direct use in patients.

The sterile eluate (gallium ( 68 Ga) chloride solution) from the radionuclide generator GalliaPharm is indicated for *in vitro* radiolabelling of various kits for radiopharmaceutical preparation developed and approved for radiolabelling with such eluate, to be used for positron emission tomography (PET) imaging.

## Authorisation details

EMA product number EMEA/H/C/006053 Marketing authorisation holder

Eckert &amp; Ziegler Radiopharma GmbH

Robert-Rossle-Str. 10 D-13125 Berlin Germany

Opinion adopted 30/05/2024 Marketing authorisation issued 01/08/2024

## Assessment history

## Initial marketing authorisation documents

GalliaPharm : EPAR - Public assessment report

Adopted

Reference Number: EMA/285852/2024

English (EN) (1.63 MB - PDF)

**First published:** 22/08/2024

[View](/en/documents/assessment-report/galliapharm-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for GalliaPharm

Reference Number: EMA/CHMP/149530/2024

English (EN) (183.61 KB - PDF)

**First published:** 31/05/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-galliapharm_en.pdf)

#### News on GalliaPharm

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-may-2024) 31/05/2024

**This page was last updated on** 22/08/2024

## Share this page

[Back to top](#main-content)